CN1245189C - 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 - Google Patents
一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 Download PDFInfo
- Publication number
- CN1245189C CN1245189C CN 200410062488 CN200410062488A CN1245189C CN 1245189 C CN1245189 C CN 1245189C CN 200410062488 CN200410062488 CN 200410062488 CN 200410062488 A CN200410062488 A CN 200410062488A CN 1245189 C CN1245189 C CN 1245189C
- Authority
- CN
- China
- Prior art keywords
- radix
- fructus
- substitute
- equivalent
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 210000003734 kidney Anatomy 0.000 title claims abstract description 16
- 230000017531 blood circulation Effects 0.000 title claims abstract description 11
- 210000004369 blood Anatomy 0.000 title claims description 26
- 239000008280 blood Substances 0.000 title claims description 26
- 230000001737 promoting effect Effects 0.000 title claims 5
- 238000005728 strengthening Methods 0.000 title abstract description 5
- 210000000952 spleen Anatomy 0.000 title abstract description 3
- 239000002184 metal Substances 0.000 title 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 72
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 71
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 71
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 71
- 235000008434 ginseng Nutrition 0.000 claims abstract description 71
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 201000007094 prostatitis Diseases 0.000 claims abstract description 14
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 11
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 208000007443 Neurasthenia Diseases 0.000 claims abstract description 9
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 9
- 206010003549 asthenia Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 175
- 241000208340 Araliaceae Species 0.000 claims description 69
- 235000003935 Hippophae Nutrition 0.000 claims description 44
- 241000229143 Hippophae Species 0.000 claims description 44
- 239000009636 Huang Qi Substances 0.000 claims description 44
- 239000002994 raw material Substances 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 24
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 16
- 206010036596 premature ejaculation Diseases 0.000 claims description 11
- 230000001568 sexual effect Effects 0.000 claims description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 9
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 9
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims 4
- 239000000463 material Substances 0.000 claims 3
- 208000016255 tiredness Diseases 0.000 claims 1
- 230000003867 tiredness Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 11
- 210000002307 prostate Anatomy 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 abstract description 2
- 230000036299 sexual function Effects 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 3
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 235000011034 Rubus glaucus Nutrition 0.000 abstract 2
- 244000235659 Rubus idaeus Species 0.000 abstract 2
- 235000009122 Rubus idaeus Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000893536 Epimedium Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 40
- 230000007812 deficiency Effects 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 15
- 239000000787 lecithin Substances 0.000 description 15
- 229940067606 lecithin Drugs 0.000 description 15
- 235000010445 lecithin Nutrition 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000003127 knee Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000009205 Tinnitus Diseases 0.000 description 11
- 210000000038 chest Anatomy 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 231100000886 tinnitus Toxicity 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229960003604 testosterone Drugs 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 208000019914 Mental Fatigue Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000000115 thoracic cavity Anatomy 0.000 description 7
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 231100000889 vertigo Toxicity 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- CMVHOLZLFLESKY-UHFFFAOYSA-N Anisodine Natural products CN1C2CC(CC1C3OC23)C(=O)OC(O)(CO)c4ccccc4 CMVHOLZLFLESKY-UHFFFAOYSA-N 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- JEJREKXHLFEVHN-QDXGGTILSA-N anisodine Chemical compound C1([C@](O)(CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 JEJREKXHLFEVHN-QDXGGTILSA-N 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000004908 prostatic fluid Anatomy 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 206010029446 nocturia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010037528 lactotropin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000007105 physical stamina Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(ml/kg) | 动物数(只) | 存活时间(min) | 延长率(%) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 1212111212 | 26.1±3.6049.0±2.9*40.0±3.8*35.1±7.445.3±6.2* | 87.753.334.473.5 |
组别 | 剂量(ml/kg) | 动物数(只) | 聚集抑制率(%) |
对照该药口服该药口服该药口服对照药口服 | 107.5565mg | 44444 | 27.0±4.362.0±12.9**53.0±5.4*45.0±3.7*59.0±8.5** |
组别 | 剂量(ml/kg) | 动物数(只) | 总胆固醇(mg) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 1010101010 | 386.0±46.0265.0±63.0*277.0±39.1*302.0±75.0*297.0±24.0* |
组别n=10 | OD值( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 0.7183±0.26200.7870±0.16601.2530±0.39350.8968±0.0430.8550±0.073 | 0.703.5772.1261.589 | <0.05<0.01<0.05<0.05 |
组别n=10 | OD值( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 15.78±6.1320.14±7.2129.57±3.1528.79±3.0625.12±2.22 | 1.4576.3276.0054.53 | >0.05<0.01<0.01<0.01 |
组别 | 剂量(ml/kg) | 动物数(只) | 吞噬指数(OD%) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 1010101010 | 0.029±0.0120.070±0.013**0.04±0.007*0.03±0.0060.038±0.009* |
组别 | 剂量(ml/kg) | 动物数(只) | 自主活动次数 | 抑制率(%) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 109101010 | 432.0±97.0295.0±124.0*323.0±56.0*343.0±74.0302.4±60.0* | 31.725.220.630.0 |
组别n=10 | 剂量 | 错误次数 | t | p | |
记忆障碍药樟柳碱10mg/kg | 对照组樟柳碱该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组)对照药口服 | 0030ml/kg24ml/kg18ml/kg270mg/kg | 1.24±0.463.83±2.451.79±0.711.81±1.121.95±1.102.23±1.31 | 2.532.372.211.82 | <0.05<0.05<0.05>0.05 |
组别 | 剂量(ml/kg) | 动物数(只) | 游泳持续时间(分) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 121112910 | 41±1264±21*57±11*45±759±17* |
组别 | 剂量(ml/kg) | 动物数(只) | 存活时间(min) | 延长率(%) |
对照该药口服该药口服该药口服对照药口服 | 201510135mg | 109101010 | 39.0±9.554.0±5.9*48.0±6.9*42.0±7.352.3±10.2* | 38.523.17.734.1 |
组别n=10 | 时间(分)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 62±1170±1381±1375±866±5 | 1.493.533.021.05 | >0.05<0.01<0.01>0.05 |
组别n=10 | 时间(分)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 28±431±839±934±632±5 | 1.063.532.631.98 | >0.05<0.01<0.05>0.05 |
组别n=10 | 微微克/ml血浆( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 43.25±8.2346.77±9.8654.27±10.2351.89±6.3147.46±8.52 | 0.8672.6542.63351.124 | >0.05<0.05<0.05>0.05 |
组别n=10 | 微微克/ml血浆( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 51.45±7.2455.26±9.4667.57±8.2363.16±7.8956.88±9.65 | 1.0124.6503.4581.423 | >0.05<0.01<0.01>0.05 |
组别n=10 | SOD(OD值)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 0.1417±0.01270.1569±0.01640.1773±0.01560.1635±0.0240.1597±0.011 | 2.31735.59642.53893.3879 | <0.05<0.01<0.05<0.01 |
组别n=10 | GSH-px(EV)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 0.2235±0.01730.2578±0.01320.2766±0.01140.2674±0.01250.2379±0.0129 | 4.988.106.502.37 | <0.01<0.01<0.01<0.05 |
组别n=10 | MAO-B(OD值)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 0.2821±0.03280.2431±0.02910.2295±0.01830.2347±0.0210.2397±0.0154 | 2.814.433.843.70 | <0.05<0.01<0.01<0.01 |
组别n=10 | LPO(OD值)( X±SD) | t | p |
对照对照药口服该药口服(高剂量组)该药口服(中剂量组)该药口服(低剂量组) | 0.1342±0.01630.1215±0.02410.0979±0.03120.1019±0.04190.1182±0.0124 | 1.383.262.272.4705 | >0.05<0.01<0.05<0.05 |
证候 | 治疗前症状 | 治疗后 | 例数 | 显效 | 有效 | 无效 |
心气虚证肾气虚证心肾气虚 | 气怯神疲,气短无力,胸闷自汗,心悸等腰膝酸软,眩晕耳鸣,遗精早泄,尿后余沥心悸、失眠、健忘,腰膝酸软、头晕耳鸣 | 症状消失症状消失症状消失 | 583418 | 2298 | 312310 | 520 |
证候 | 治疗前症状 | 治疗后 | 例数 | 显效 | 有效 | 无效 |
心气虚证肾气虚证心肾气虚气虚兼血瘀 | 气怯神疲,气短无力,胸闷自汗,心悸等腰膝酸软,眩晕耳鸣,遗精早泄,尿后余沥心悸、失眠、健忘,腰膝酸软、头晕耳鸣气怯神疲,心悸、胸闷、胸背刺痛、肢体麻木 | 症状消失症状消失症状消失症状消失 | 20303020 | 11191811 | 7997 | 2232 |
病例 | 治疗前 | 治疗后第一疗程 | 治疗后第二疗程 |
12例 | 卵磷脂小体≥50%白细胞≥10/HP | 卵磷脂小体≥70%白细胞≥5-10/HP | 卵磷脂小体≥80%白细胞≥0-1/HP |
10例 | 卵磷脂小体≥30%白细胞≥20/HP | 卵磷脂小体≥80%白细胞≥3-5/HP | 卵磷脂小体≥80%白细胞≥0-1/HP |
2例 | 卵磷脂小体≥50%白细胞≥3-5/HP | 化验标本未取出 | 卵磷脂小体≥70%白细胞≥0-1/HP |
4例 | 卵磷脂小体≥30%白细胞≥2-3/HP | 卵磷脂小体≥30%白细胞≥2-5/HP | 卵磷脂小体≥30%白细胞≥3-5/HP |
总有效率:86.71%(注:取前列腺标本失败即化验标本未取出) |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410062488 CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410062488 CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1586533A CN1586533A (zh) | 2005-03-02 |
CN1245189C true CN1245189C (zh) | 2006-03-15 |
Family
ID=34603713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410062488 Expired - Lifetime CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1245189C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464776C (zh) * | 2006-01-10 | 2009-03-04 | 天津市东方虹膜医学技术研究开发中心 | 扶正清浊散 |
CN101760390B (zh) * | 2009-12-10 | 2012-05-30 | 神农架神农氏生物开发有限公司 | 一种养身酒的生产方法 |
CN103239509B (zh) * | 2013-05-06 | 2014-09-03 | 陕西立众制药有限公司 | 一种用于益气健脾、补肾宁心的中药组合物及其制备方法 |
CN104189695A (zh) * | 2014-09-17 | 2014-12-10 | 兰成然 | 一种主治尿失禁的中草药制剂及其制作方法 |
CN104645229B (zh) * | 2015-02-04 | 2018-02-13 | 北京全净通一科技有限公司 | 一种五行药浴散及制备方法 |
CN105031203A (zh) * | 2015-08-21 | 2015-11-11 | 河北工程大学 | 治疗老年痴呆的中药组合物 |
CN107495367B (zh) * | 2017-08-24 | 2020-11-20 | 四川省中医药科学院 | 一种提高耐缺氧能力的食品、保健品或药物组合物及其制备方法和用途 |
CN108578522A (zh) * | 2018-07-02 | 2018-09-28 | 成荣富 | 一种治疗前列腺炎的中草药 |
CN109793834A (zh) * | 2019-03-30 | 2019-05-24 | 漯河医学高等专科学校 | 一种提高免疫力的中药配方 |
CN114010740A (zh) * | 2021-11-26 | 2022-02-08 | 建和复元生物科技(深圳)有限公司 | 一种具有脱发再生修护前列腺功能的药酒 |
-
2004
- 2004-07-12 CN CN 200410062488 patent/CN1245189C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1586533A (zh) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245189C (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1709376A (zh) | 治疗气滞型胃脘痛的中药复方制剂及其制备方法 | |
CN1813868A (zh) | 一种治疗和改善慢性疲劳综合症的组合物及其制备方法 | |
CN1917895A (zh) | 鱼腥草和插田泡的提取物及其用于预防和治疗过敏性疾病的组合物 | |
CN1284587C (zh) | 一种治疗消化道肿瘤的中药制剂 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1232267C (zh) | 用于治疗脑血管疾病的组合物及其制备方法和应用 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1833695A (zh) | 一种健脾益肾颗粒及其制备方法 | |
CN1973872A (zh) | 滋阴补肾强身健脑的药物及制备方法 | |
CN1221280C (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN101036722A (zh) | 一种缓解疲劳、改善男性更年期综合征的保健食品及制备 | |
CN1194735C (zh) | 一种治疗乳腺增生的中药 | |
CN1264537C (zh) | 一种能改善男性阳痿症状的胶囊 | |
CN1686485A (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1857495A (zh) | 一种治疗痛证的中药复方制剂及其制备方法 | |
CN1323692C (zh) | 治疗肾虚腰痛的药物组合物及其制备方法 | |
CN1868502A (zh) | 一种用于治疗类风湿性关节炎的药物组合物及其制备方法 | |
CN1931346A (zh) | 一种抗癌软胶囊及其制备方法 | |
CN1222305C (zh) | 治疗肝肾不足、气阴亏虚的中药及其制备方法 | |
CN1162177C (zh) | 一种治疗脂肪肝的药物 | |
CN1899581A (zh) | 用于气滞寒凝胃痛的药物组合物及其制备方法和用途 | |
CN1282470C (zh) | 一种抗抑郁中药及其制备方法 | |
CN1308023C (zh) | 治疗充血性心力衰竭的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060315 Termination date: 20120712 |
|
C49 | Reinstatement of patent right or utility model | ||
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20130904 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210622 Address after: 102629 2-1113, yard 9, Huatuo Road, Daxing District, Beijing Patentee after: Sun Shuming Patentee after: Liu Hongwei Address before: 100044, room 6, building 253, Yiyuan garden, Beijing Jiaotong University, Beijing, Haidian District Patentee before: Sun Shuming |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060315 |
|
CX01 | Expiry of patent term |